1,4-二甲基-2,3-二氢喹喔啉 | 2427-06-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1,4-二甲基-2,3-二氢喹喔啉
• 英文名称: 1,4-dimethyl-1,2,3,4-tetrahydroquinoxaline
• 英文别名: 1,4-dimethyl-1,2,3,4-tetrahydro-quinoxaline；1,4-Dimethyl-1,2,3,4-tetrahydro-chinoxalin；1,4-Dimethyl-1,2,3,4-tetrahydrochinoxalin；Quinoxaline, 1,2,3,4-tetrahydro-1,4-dimethyl-；1,4-dimethyl-2,3-dihydroquinoxaline
• CAS: 2427-06-7
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: XGJGSZQCWARFIA-UHFFFAOYSA-N

物化性质

• 沸点：
  92-94 °C(Press: 1 Torr)
• 密度：
  1.024±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,4-二甲基-2,3-二氢喹喔啉 以9%的产率得到
  参考文献：
  名称：

  MRACHKOVSKAYA L. B.; TURCHIN K. F.; YAXONTOV L. N., XIMIYA GETEROTSIKL. SOEDIN. , 1976, HO 2, 272-275

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(3-chloro-phenyl)-N,N'-dimethyl-ethylenediamine 在 乙醚 、 sodium amide 作用下， 生成 1,4-二甲基-2,3-二氢喹喔啉
  参考文献：
  名称：

  Koenig; Huisgen, Chemische Berichte, 1959, vol. 92, p. 429,435

  摘要：

  DOI：

文献信息

• TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Namane Claudie

  公开号：US20120135958A1

  公开（公告）日：2012-05-31

  The invention relates to compounds of formula (I), where: A is a bond, an oxygen, or an —CH 2 — group; Ar 1 is a phenyl or heteroaryl group; Ar 2 is a phenyl, heteroaryl, or heterocycloalkyl group; R 1a,b,c and R 2a,b,c are hydrogen or halogen, or an alkyl, cycloalkyl, or lkyl-cycloalkyl group optionally, substituted by one or more halogen atoms, or a —OR 5 (hydroxy or alkoxy), hydroxy-alkyl, alkoxy-alkyl, alkoxy-alkoxy, halogenoalkyl, —O-halogenoalkyl, oxo, —CO-alkyl, —CO-alkyl-NR 6 R 7 , —CO-halogenoalkyl, —COOR 5 , alkyl-COOR 5 , —O-alkyl-COOR 5 , —SO 2 -alkyl, —SO 2 -cycloalkyl, —SO 2 -alkyl-cycloalkyl, —SO 2 -alkyl-OR 5 , —SO 2 -alkyl-COOR 5 , —SO 2 -alkyl-NR 6 R 7 , —SO 2 -halogenoalkyl, alkyl-SO 2 -alkyl, —SO 2 —NR 6 R 7 , —SO 2 -alkyl-O-alkyl-OR 5 , —CONR 6 R 7 , -alkyl-CONR 6 R 7 , or -alkyl-NR 6 R 7 group, or further R 1a , R 1b , and R 1c are bonded to R 2a , R 2b , R 2c , respectively, and to the carbon atom having same, and are -alkyl-O—; R 3 is a hydrogen atom or an alkyl group; R 4 is a hydrogen or halogen atom or a cyano, —OR 5 , hydroxyalkyl, —COOR 5 , —NR 6 R 7 , ONR 6 R 7 , —SO 2 -alkyl, SO 2 —NR 6 R 7 , —NR 6 —COOR 5 , —NR 6 —COR 5 , or —CO—NR 6 -alkyl-OR 5 group; R 5 , R 6 , and R 7 are a hydrogen, or an alkyl or alkyl-phenyl group; and R 8 is an alkyl, alkyl-Si(alkyl) 3 , —SO 2 -alkyl-Si(alkyl) 3 , phenyl, alkoxy-imino group, or alkyl-cycloalkyl group optionally substituted by one or more halogen atoms or one or more hydroxyl or hydroxyl-alkyl groups; or R 8 and R 9 , together with the carbon atoms to which they are bonded, form a cycloalkyl group optionally substituted by one or more halogen atoms or one or more carboxy groups; and R 9 is a hydrogen atom or an alkyl group; with the proviso that, when R 8 is an alkyl group, it is bonded onto the Ar 2 silicon atom. The invention also relates to a method for preparing same and to the therapeutic use thereof.

  该发明涉及公式(I)的化合物，其中：A是一个键，一个氧或一个—CH2—基团；Ar1是一个苯基或杂环芳基；Ar2是一个苯基，杂环芳基或杂环烷基基团；R1a，b，c和R2a，b，c是氢或卤素，或一个烷基，环烷基或烷基-环烷基基团，可以被一个或多个卤素原子取代，或一个—OR5（羟基或烷氧基），羟基-烷基，烷氧基-烷基，烷氧基-烷氧基，卤代烷基，—O-卤代烷基，酮基，—CO-烷基，—CO-烷基-NR6R7，—CO-卤代烷基，—COOR5，烷基-COOR5，—O-烷基-COOR5，—SO2-烷基，—SO2-环烷基，—SO2-烷基-环烷基，—SO2-烷基-OR5，—SO2-烷基-COOR5，—SO2-烷基-NR6R7，—SO2-卤代烷基，烷基-SO2-烷基，—SO2-NR6R7，—SO2-烷基-O-烷基-OR5，—CONR6R7，-烷基-CONR6R7，或-烷基-NR6R7基团，或进一步的R1a，R1b和R1c与R2a，R2b和R2c分别结合，并与具有相同的碳原子结合，并且是-烷基-O-；R3是氢原子或烷基基团；R4是氢或卤素原子或氰基，—OR5，羟基烷基，—COOR5，—NR6R7，ONR6R7，—SO2-烷基，SO2-NR6R7，—NR6—COOR5，—NR6—COR5，或—CO—NR6-烷基-OR5基团；R5，R6和R7是氢，或烷基或烷基-苯基基团；R8是一个烷基，烷基-Si（烷基）3，—SO2-烷基-Si（烷基）3，苯基，烷氧基-亚胺基团，或烷基-环烷基基团，可以被一个或多个卤素原子或一个或多个羟基或羟基-烷基基团取代；或R8和R9，与它们结合的碳原子一起，形成一个可以被一个或多个卤素原子或一个或多个羧基取代的环烷基基团；R9是氢原子或烷基基团；但是，当R8是烷基基团时，它与Ar2硅原子结合。该发明还涉及制备该化合物的方法和其治疗用途。
• TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
  申请人：BRAUN Alain Jean

  公开号：US20110009391A1

  公开（公告）日：2011-01-13

  The present invention relates to tetrahydroquinoxaline urea derivatives, to their preparation and to their therapeutic application.

  本发明涉及四氢喹噁啉脲衍生物，其制备方法及其治疗应用。
• ORGANIC LIGHT-EMITTING DIODE MATERIALS
  申请人：President and Fellows of Harvard College

  公开号：US20180212158A1

  公开（公告）日：2018-07-26

  Described herin are molecules for use in organic light emitting diodes. Example molecules comprise at least one acceptor moiety A, at least one donor moiety D, and optionally one or more bridge moieties B. Each moiety A is covalently attached to either the moiety B or the moeity D, each moiety D is covalently attached to either the moeity B or the moeity A, and each B is covalently attached to at least one moiety A and at least one moiety D. Values and preferred values of moieties A, D and B are defined herein.

  本文描述了用于有机发光二极管的分子。示例分子包括至少一个受体基团A，至少一个给体基团D，以及可选地一个或多个桥接基团B。每个基团A与基团B或基团D中的任一基团共价连接，每个基团D与基团B或基团A中的任一基团共价连接，每个基团B与至少一个基团A和至少一个基团D共价连接。这里定义了基团A、D和B的值和首选值。
• Utilization of renewable formic acid from lignocellulosic biomass for the selective hydrogenation and/or N‐methylation
  作者：Chao‐Zheng Zhou、Yu‐Rou Zhao、Fang‐Fang Tan、Yan‐Jun Guo、Yang Li

  DOI：10.1002/cctc.202101099

  日期：2021.11.22

  Lignocellulosic biomass is one of the most abundant renewable sources in nature. Herein, we have developed the utilization of renewable formic acid from lignocellulosic biomass as a hydrogen source and a carbon source for the selective hydrogenation and further N-methylation of various quinolines and the derivatives, various indoles under mild conditions in high efficiencies. N-methylation of various

  木质纤维素生物质是自然界中最丰富的可再生资源之一。在此，我们开发了利用木质纤维素生物质中的可再生甲酸作为氢源和碳源，在温和条件下高效地对各种喹啉及其衍生物、各种吲哚进行选择性加氢和进一步 N-甲基化。还开发了各种苯胺的 N-甲基化。机理研究表明氢化通过转移氢化途径发生。
• NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF
  申请人：TEMPLE UNIVERSITY OF THE COMMONWEALTH

  公开号：US20160229841A1

  公开（公告）日：2016-08-11

  Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in it etiology.

  本发明的药物组合物包括化合物、组合物、用于治疗药物成瘾、药物戒断以及涉及谷氨酸稳态失调的疾病或症状的方法。